MX2017005668A - Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. - Google Patents
Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2.Info
- Publication number
- MX2017005668A MX2017005668A MX2017005668A MX2017005668A MX2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A
- Authority
- MX
- Mexico
- Prior art keywords
- synthase
- carboxylic acid
- acid compounds
- compounds useful
- microsomal prostaglandin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula 1, o sales farmacéuticamente aceptables de los mismos, donde R, X, A, E y G son como se describen en la presente, métodos para preparar los compuestos y uso de los compuestos para tratar dolor y/o inflamación (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072140P | 2014-10-29 | 2014-10-29 | |
PCT/US2015/056955 WO2016069374A1 (en) | 2014-10-29 | 2015-10-22 | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005668A true MX2017005668A (es) | 2017-06-26 |
Family
ID=54365459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005668A MX2017005668A (es) | 2014-10-29 | 2015-10-22 | Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. |
Country Status (16)
Country | Link |
---|---|
US (2) | US9969714B2 (es) |
EP (1) | EP3221304B1 (es) |
JP (1) | JP6425809B2 (es) |
KR (1) | KR101903304B1 (es) |
CN (1) | CN107001319B (es) |
AR (1) | AR102361A1 (es) |
AU (1) | AU2015339737B2 (es) |
BR (1) | BR112017006809B1 (es) |
CA (1) | CA2963318C (es) |
CL (1) | CL2017001050A1 (es) |
EA (1) | EA031504B1 (es) |
ES (1) | ES2744211T3 (es) |
MX (1) | MX2017005668A (es) |
NZ (1) | NZ730730A (es) |
TW (1) | TW201627299A (es) |
WO (1) | WO2016069374A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3581B1 (ar) | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
KR20220106998A (ko) * | 2019-11-27 | 2022-08-01 | 스미토모 파마 가부시키가이샤 | 시클로알킬 우레아 유도체 |
US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355010B1 (en) | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
WO2004103954A1 (ja) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
US20050239921A1 (en) | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
EP1831194A4 (en) * | 2004-12-21 | 2009-12-02 | Astrazeneca Ab | HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF |
WO2008131047A2 (en) | 2007-04-16 | 2008-10-30 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism |
UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
EP2491007B1 (en) | 2009-10-23 | 2013-09-25 | Boehringer Ingelheim International GmbH | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
WO2013146970A1 (ja) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
CN105658645A (zh) | 2013-06-20 | 2016-06-08 | 诺瓦赛德股份公司 | 作为mpge-1抑制剂的哌啶基苯并咪唑衍生物 |
JO3581B1 (ar) | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
-
2015
- 2015-10-19 AR ARP150103381A patent/AR102361A1/es unknown
- 2015-10-19 TW TW104134251A patent/TW201627299A/zh unknown
- 2015-10-22 AU AU2015339737A patent/AU2015339737B2/en active Active
- 2015-10-22 MX MX2017005668A patent/MX2017005668A/es active IP Right Grant
- 2015-10-22 EA EA201790764A patent/EA031504B1/ru not_active IP Right Cessation
- 2015-10-22 KR KR1020177011302A patent/KR101903304B1/ko active IP Right Grant
- 2015-10-22 CN CN201580058924.XA patent/CN107001319B/zh active Active
- 2015-10-22 ES ES15787859T patent/ES2744211T3/es active Active
- 2015-10-22 JP JP2017522854A patent/JP6425809B2/ja active Active
- 2015-10-22 US US15/520,078 patent/US9969714B2/en active Active
- 2015-10-22 BR BR112017006809-5A patent/BR112017006809B1/pt active IP Right Grant
- 2015-10-22 WO PCT/US2015/056955 patent/WO2016069374A1/en active Application Filing
- 2015-10-22 EP EP15787859.6A patent/EP3221304B1/en active Active
- 2015-10-22 CA CA2963318A patent/CA2963318C/en active Active
- 2015-10-22 NZ NZ730730A patent/NZ730730A/en unknown
-
2017
- 2017-04-27 CL CL2017001050A patent/CL2017001050A1/es unknown
-
2018
- 2018-05-08 US US15/974,076 patent/US20180251446A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN107001319B (zh) | 2019-10-01 |
BR112017006809B1 (pt) | 2023-02-23 |
NZ730730A (en) | 2018-08-31 |
CN107001319A (zh) | 2017-08-01 |
AU2015339737B2 (en) | 2018-03-15 |
AR102361A1 (es) | 2017-02-22 |
TW201627299A (zh) | 2016-08-01 |
EP3221304A1 (en) | 2017-09-27 |
WO2016069374A1 (en) | 2016-05-06 |
AU2015339737A1 (en) | 2017-04-20 |
CA2963318C (en) | 2019-06-25 |
US20180251446A1 (en) | 2018-09-06 |
JP2018500280A (ja) | 2018-01-11 |
BR112017006809A2 (pt) | 2017-12-26 |
ES2744211T3 (es) | 2020-02-24 |
JP6425809B2 (ja) | 2018-11-21 |
EP3221304B1 (en) | 2019-07-24 |
EA031504B1 (ru) | 2019-01-31 |
KR101903304B1 (ko) | 2018-10-01 |
CA2963318A1 (en) | 2016-05-06 |
US20170313679A1 (en) | 2017-11-02 |
CL2017001050A1 (es) | 2018-01-12 |
KR20170063828A (ko) | 2017-06-08 |
US9969714B2 (en) | 2018-05-15 |
EA201790764A1 (ru) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
NZ730724A (en) | Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
PH12015501755A1 (en) | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders | |
TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
PH12016501462A1 (en) | Neprilysin inhibitors | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
UA115583C2 (uk) | Азетидинілоксифенілпіролідинові сполуки | |
MX2015011375A (es) | Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1]. | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
TN2015000524A1 (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |